about
Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbensElevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and CaffeinePharmacological treatment of comorbid PTSD and substance use disorder: recent progressThe norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humansβ1-Adrenergic receptors activate two distinct signaling pathways in striatal neuronsPharmacological treatments for methamphetamine addiction: current status and future directions.Cocaine sensitization increases I h current channel subunit 2 (HCN₂) protein expression in structures of the mesocorticolimbic system.Cognitive enhancement as a pharmacotherapy target for stimulant addictionCocaine modulates mammalian circadian clock timing by decreasing serotonin transport in the SCN.Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors.Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis.Cognitive enhancers in the treatment of substance use disorders: clinical evidence.The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions.Analytical approach to determine biogenic amines in urine using microextraction in packed syringe and liquid chromatography coupled to electrochemical detection.Off-label use of atomoxetine in adults: is it safe?Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence.Effects of the combination of wheel running and atomoxetine on cue- and cocaine-primed reinstatement in rats selected for high or low impulsivity.Prenatal Stress Alters Progestogens to Mediate Susceptibility to Sex-Typical, Stress-Sensitive Disorders, such as Drug Abuse: A Review.A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.Imaging Mass Spectrometric Analysis of Neurotransmitters: A Review.Dopamine and serotonin genetic risk scores predicting substance and nicotine use in attention deficit/hyperactivity disorder.Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteersPsychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms.Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways.Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion.Methamphetamine regulation of sulfotransferase 1A1 and 2A1 expression in rat brain sectionsEvaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial.Emerging role for corticotropin releasing factor signaling in the bed nucleus of the stria terminalis at the intersection of stress and reward.Sex differences in reinstatement of cocaine-seeking with combination treatments of progesterone and atomoxetineSusceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestryDifferential effects of acute and chronic treatment with the α2-adrenergic agonist, lofexidine, on cocaine self-administration in rhesus monkeys.Review of recent advances in analytical techniques for the determination of neurotransmittersSex-specific dissociations in autonomic and HPA responses to stress and cues in alcohol-dependent patients with cocaine abuse.Cocaine self-administration and extinction alter medullary noradrenergic and limbic forebrain cFos responses to acute, noncontingent cocaine injections in adult rats.Preclinical evidence of new opioid modulators for the treatment of addiction.
P2860
Q22248089-2FE91128-8BB9-4327-9894-2389D2AA4E09Q24608522-0A8489D3-5042-4E29-9C52-BCE94288FC97Q27022219-89F0DD45-39C2-489F-B2B2-029E1D307BB2Q28240897-F4A1B422-D1F5-4025-96B6-B603D176A796Q28581364-0A5E080A-9DA7-4AE4-AFB0-189B422CAA67Q30240173-6E7B33C7-65A7-4B22-A6F4-EBCF30DE0630Q30439200-BB524F74-84C6-41F1-9804-28913F228D40Q33599983-D17B2833-D3A7-4594-B204-E4CA37FB7DEFQ34006034-7251463D-FE8D-4FA5-8D45-1B698EFEC955Q34130038-A386051A-826B-4393-9C3B-310523989DA6Q34130247-B44083BA-7006-4511-9036-45F45D8183D5Q34183988-FB468416-4165-4239-B570-C373A8872FD4Q34363257-C960ABA6-CF14-44EB-80C6-04E21FCF0DBDQ34407185-34F3381D-E14A-4843-B9A2-5178B336A965Q34424490-2BEB9F93-056E-420C-BC71-1A85AAC76DCCQ34466369-6D2BD636-E551-4D32-9207-0B723A05770FQ34618993-6B1AD3B7-8147-4D4A-A2D0-9D0C816431DAQ34756340-26950C21-640D-4ECF-B209-424471644639Q35117860-74130F43-9009-4EA6-BDE0-52822AFF84C3Q35367349-E36AD81F-5385-403D-8C96-2E35D0ECD084Q35489643-B39C668E-0551-4C1D-8A97-0C8A4EDFD724Q35906825-41C871BB-4242-4849-9297-1FE1EA93D11DQ36031700-C8BF0496-C21B-4E23-8D46-CD4D24E3BB40Q36139962-8157122C-12CA-4049-903D-1908325E53EAQ36144909-E341B653-D6BD-4AF3-92CA-1DB1563E3AB6Q36174329-A4AF716B-626B-42A6-8819-3A2109ACE9A7Q36252777-6EFAD60A-8A60-442F-AFD9-4D6A8448585CQ36388933-FB6381E2-74DE-4A5E-A13E-092DE6436F59Q36569909-D007C0F6-8CD0-4E27-A0B7-5D62C31349FDQ36650526-1C7736FF-F63F-44FC-A8A5-4A78F73CFEA1Q36847296-B0EE7044-6B05-4223-97AF-CEBD9D190CB4Q36857705-BDB71320-5123-4695-9ACB-55437107D4A5Q36881952-AC24AEE4-4A3A-4E87-B383-B8F54DBDC3EDQ36892871-AA02294E-B579-4085-97E7-7CE8C1274AD9Q36976562-FCA14AE8-A744-4166-B755-CE06FA587695Q37281980-45B6323E-964B-459F-B1EB-3D9CAF16BF8BQ37381103-66572161-FE25-48F3-82E3-CE55F431AA55Q37432409-922BB623-4410-48B1-A02B-2ADCE7DE13B2Q37505035-067828C3-3A87-4421-8DAB-B5A092087878Q37772519-CA141FF2-0F18-4ABA-8712-ED7DF1108421
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Norepinephrine and stimulant addiction
@ast
Norepinephrine and stimulant addiction
@en
Norepinephrine and stimulant addiction
@nl
type
label
Norepinephrine and stimulant addiction
@ast
Norepinephrine and stimulant addiction
@en
Norepinephrine and stimulant addiction
@nl
prefLabel
Norepinephrine and stimulant addiction
@ast
Norepinephrine and stimulant addiction
@en
Norepinephrine and stimulant addiction
@nl
P2860
P3181
P1433
P1476
Norepinephrine and stimulant addiction
@en
P2093
Mehmet Sofuoglu
R Andrew Sewell
P2860
P304
P3181
P356
10.1111/J.1369-1600.2008.00138.X
P407
P577
2009-04-01T00:00:00Z